GSK Flonase suit
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline has dropped its lawsuit disputing FDA's approval of generic Flonase (fluticasone propionate). GSK decided not to appeal the March 6 ruling of Baltimore federal court Judge Andre Davis that denied the firm's request for a preliminary injunction on the sale of the generic nasal spray. FDA's approval of the generic nasal spray Feb. 22 prompted GSK to file suit; the court granted the firm a temporary restraining order suspending FDA approval of the drug until March 6 (1"The Tan Sheet" Feb. 27, 2006, p. 4). GSK discontinued plans for an Rx-to-OTC switch of Flonase in favor of pursuing legal action against the sale of generics, and now says it has no plans to resume a switch program...
You may also be interested in...
Flonase Generic Launch Blocked; Glaxo Drops Switch Plan
GlaxoSmithKline has shelved an OTC switch of Flonase nasal steroid as a competitive strategy in favor of litigation to block generics
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.